Stereotaxis (STXS) 10-Q 14 May 18 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2018	Apr. 30, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	Stereotaxis, Inc.
Entity Filer Category	Smaller Reporting Company
Entity Central Index Key	1,289,340
Trading Symbol	stxs
Amendment Flag	false
Document Type	10-Q
Document Fiscal Period Focus	Q1
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		58,926,619

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 11,613,713	$ 3,686,302
Accounts receivable, net of allowance of $303,688 and $361,350 in 2018 and 2017, respectively	6,637,588	4,287,255
Inventories, net	1,446,574	1,146,971
Prepaid expenses and other current assets	742,075	750,085
Total current assets	20,439,950	9,870,613
Property and equipment, net	462,213	592,688
Intangible assets, net	142,973	159,470
Other assets	282,199	44,432
Total assets	21,327,335	10,667,203
Current liabilities:
Accounts payable	1,819,423	1,654,101
Accrued liabilities	2,947,677	3,195,247
Deferred revenue	7,136,065	5,702,769
Warrants		19,574,977
Total current liabilities	11,903,165	30,127,094
Long-term deferred revenue	560,649	611,863
Other liabilities	580,866	535,369
Total liabilities	13,044,680	31,274,326
Convertible Preferred stock:
Convertible Preferred stock, par value $0.001; 10,000,000 shares authorized, 23,900 shares outstanding at 2018 and 2017	5,960,475	5,960,475
Stockholders' deficit:
Common stock, par value $0.001; 300,000,000 shares authorized, 58,901,126 and 22,805,731 shares issued at 2018 and 2017, respectively	58,901	22,806
Additional paid in capital	477,872,296	450,748,403
Treasury stock, 4,015 shares at 2018 and 2017	(205,999)	(205,999)
Accumulated deficit	(475,403,018)	(477,132,808)
Total stockholders' equity (deficit)	2,322,180	(26,567,598)
Total liabilities and stockholders' equity (deficit)	$ 21,327,335	$ 10,667,203

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Balance Sheets [Abstract]
Accounts receivable, allowance	$ 303,688	$ 361,350
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	23,900	23,900
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	58,901,126	22,805,731
Treasury stock, shares	4,015	4,015

Statements Of Operations

Statements Of Operations - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue:
Systems	$ 17,275	$ 218,895
Disposables, service and accessories	6,954,357	6,758,777
Total revenue	6,971,632	6,977,672
Cost of revenue:
Systems	203,602	220,443
Disposables, service and accessories	1,061,745	1,036,182
Total cost of revenue	1,265,347	1,256,625
Gross margin	5,706,285	5,721,047
Operating expenses:
Research and development	1,962,626	1,600,877
Sales and marketing	3,634,997	3,781,448
General and administrative	1,239,179	2,241,580
Total operating expenses	6,836,802	7,623,905
Operating loss	(1,130,517)	(1,902,858)
Other income	2,590,361	3,129,308
Interest expense (net)	(24,615)	(49,483)
Net income	1,435,229	1,176,967
Cumulative dividend on convertible preferred stock	(353,589)	(363,188)
Net income attributable to convertible preferred stockholders	(610,280)	(509,323)
Net income attributable to common stockholders	$ 471,360	$ 304,456
Net income per share attributable to common stockholders:
Basic	$ 0.02	$ 0.01
Diluted	$ 0.01	$ 0.01
Weighted average number of common shares and equivalents:
Basic	30,957,648	22,318,000
Diluted	33,122,598	22,331,683

Statements Of Cash Flows

Statements Of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities
Net earnings	$ 1,435,229	$ 1,176,967
Adjustments to reconcile net earnings to cash used in operating activities:
Depreciation	140,465	140,848
Amortization of intangibles	16,497	49,831
Amortization of deferred finance costs	24,657	24,657
Share-based compensation	216,586	243,161
Loss on asset disposal		14,598
Adjustment of warrants	(2,590,361)	(3,129,308)
Changes in operating assets and liabilities:
Accounts receivable	(2,350,333)	(650,976)
Inventories	(299,603)	(277,266)
Prepaid expenses and other current assets	97,206	18,809
Other assets	(57,059)	(2,153)
Accounts payable	165,322	(407,899)
Accrued liabilities	(247,570)	(405,468)
Deferred revenue	1,382,082	536,756
Other liabilities	45,497	136
Net cash used in operating activities	(2,021,385)	(2,667,307)
Cash flows from investing activities
Purchase of fixed assets	(9,990)	(4,297)
Net cash used in investing activities	(9,990)	(4,297)
Cash flows from financing activities
Payments of deferred financing costs		(100,000)
Proceeds from issuance of stock, net of issuance costs	13,622	9,336
Proceeds from warrant exercise	9,945,164
Net cash provided by (used in) financing activities	9,958,786	(90,664)
Net increase (decrease) in cash and cash equivalents	7,927,411	(2,762,268)
Cash and cash equivalents at beginning of period	3,686,302	8,501,392
Cash and cash equivalents at end of period	$ 11,613,713	$ 5,739,124

Description Of Business

Description Of Business	3 Months Ended
	Mar. 31, 2018
Description Of Business [Abstract]
Description Of Business	1. Description of Business Stereotaxis designs, manufactures and markets the Epoch Solution, which is an advanced remote robotic navigation system for use in a hospital’s interventional surgical suite, or “interventional lab”, that we believe revolutionizes the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency, and efficacy for catheter-based, or interventional, procedures. The Epoch Solution is comprised of the Niobe ES Remote Magnetic Navigation System (“ Niobe ES system”), Odyssey Information Management Solution (“ Odyssey Solution”), and the Vdrive Robotic Navigation System (“ Vdrive system”), and related devices. The Niobe system is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures, and reduced x-ray exposure. As of March 31, 2018, the Company had an installed base of 128 Niobe ES systems. In addition to the Niobe system and its components, Stereotaxis also has developed the Odyssey Solution, which consolidates all lab information enabling doctors to focus on the patient for optimal procedure efficiency. The system also features a remote viewing and recording capability called Odyssey Cinema , which is an innovative solution delivering synchronized content for optimized workflow, advanced care, and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation, and training. Our Vdrive system provides navigation and stability for diagnostic and therapeutic devices designed to improve interventional procedures. The Vdrive system complements the Niobe ES system control of therapeutic catheters for fully remote procedures and enables single-operator workflow and is sold as two options, the Vdrive system and the Vdrive Duo system. In addition to the Vdrive system and the Vdrive Duo system, we also manufacture and market various disposable components which can be manipulated by these systems. We promote the full Epoch Solution in a typical hospital implementation, subject to regulatory approvals or clearances. The full Epoch Solution implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and software licenses. In hospitals where the full Epoch Solution has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion. The core components of Stereotaxis systems, such as the Niobe system, Odyssey Solution, Cardiodrive, and various disposable interventional devices have received regulatory clearance in the U.S., Europe, Canada, China, Japan and various other countries. We have received the regulatory clearance, licensing and/or CE Mark approvals that allow us to market the Vdrive and Vdrive Duo systems with the V-CAS , V-Loop and V-Sono devices in the U.S., Canada and European Union. The V-CAS Deflect catheter advancement system has been CE Marked for sale in the European Union. We have successfully integrated our Niobe system with digital fluoroscopy systems to provide advanced interventional lab visualization and instrument control through user-friendly computerized interfaces. The maintenance of these arrangements, or the establishment of equivalent alternatives, is critical to our commercialization efforts. The commercial availability of both currently compatible digital imaging fluoroscopy systems is unlikely to continue for multiple years and efforts are being made to ensure the availability of integrated next generation systems and/or equivalent alternatives; however, we cannot provide assurance as to the timeline of the ongoing availability of such compatible systems or our ability to obtain equivalent alternatives on competitive terms or at all. 

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited financial statements of Stereotaxis, Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and the instructions to Form 10-Q. Accordingly, they do not include all the disclosures required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, they include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Operating results for th e three month period ended March 3 1 , 201 8 are not necessarily indicative of the results that may be expected for the year ended December 31, 201 8 or for future operating periods. These interim financial statements and the related notes should be read in conjunction with the annual financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended Dec ember 31, 2017 as filed with the Securities and Exchange Commission (SEC) on Marc h 20, 201 8 .  Going Concern, Liquidity and Management’s Plan The Company believes the cash on hand at March 31, 2018 will be sufficient to meet its obligations as they become due in the ordinary course of business for at least 12 months following the date these financial statements are issued. The Company has sustained operating losses throughout its corporate history and expects that its 2018 expenses will exceed its 2018 gross margin. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations or expense reductions are in place. The Company’s liquidity needs will be largely determined by the success of clinical adoption within the installed base of Niobe systems as well as by new placements of capital systems. Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable , and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. The Company measures certain financial assets and liabilities, including warrants, at fair value on a recurring basis. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 10 for additional details. Revenue and Costs of Revenue The Company adopted ASC 606, Revenue from Contracts with Customers, on January 1, 2018 using the modified retrospective method. As part of the Company's adoption of ASC 606, the Company elected to use the following practical expedients (i) applying the modified retrospective method only to open contracts as of December 31, 2017; (ii) not to adjust the promised amount of consideration for the effects of a significant financing component when the Company expects, at contract inception, that the period between the Company's transfer of a promised product or service to a customer and when the customer pays for that product or service will be one year or less; (iii) to expense costs as incurred for costs to obtain a contract when the amortization period would have bee n one year or less; and (iv) not to assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer. Upon adoption of the new revenue guidance, the Company recorded a cumulative-effect reduction to accumulated deficit of $0.3 million on January 1, 2018 relating primarily to the deferral of previously expensed costs to obtain a contract. The Company capitalized sales commissions paid in connection with multi-year service contracts and is amortizing such asset over the economic life of those contracts. Previously, sales commissions on multi-year service contracts were expensed as incurred. The impact of this change on operating expenses in any given period will depend, in part, on the amount of such commissions incurred and capitalized in relation to the amount of ongoing amortization expense. In the first quarter of 2018, the Company recorded $0.1 million less in commission expense as a result of adopting the new standard. The Company did not otherwise experience significant changes in the timing or method of revenue recognition for any of its material revenue streams. We generate revenue from initial capital sales of systems as well as recurring revenue from the sale of our proprietary disposable devices, from royalties paid to the Company on the sale by Biosense Webster of co-developed catheters, and from other recurring revenue including ongoin g license and service contracts. We account for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We record our revenue based on consideration specified in the contract with each customer, net of any taxes collected from customers that are remitted to government authorities. For contracts containing multiple products and services the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company recognizes revenues as the performance obligations are satisfied by transferring control of the product or service to a customer. For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services and market conditions. The Company regularly reviews standalone selling price s and updates these estimates as necessary . Systems: Contracts related to the sale of systems typically contain separate obligations for the delivery of system(s), installation and an implied obligation to provide software enhancements if and when available for one year following installation. Revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. Revenue from the implied obligation to deliver software enhancements if and when available is recognized ratably over the first year following installation of the system as the customer receives the right to software updates throughout the period and is included in Other Recurring Revenue. The Company’s system contracts generally do not provide a right of return. Systems are generally covered by a one-year assurance type warranty; warranty costs were not material for the periods presented. Revenue from system delivery and installation represented less than 1% and 3% of revenue for the three months ended March 31, 2018 and 2017, respectively. Disposables: Revenue from sales of disposable products is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but can also occur at the time of delivery depending on the customer arrangement. Disposable products are covered by a n assurance type warranty that provides for the return of defective products. Warranty costs were not material for the periods presented. Disposable revenue represented 37% and 40% of revenue for the three months ended March 31, 2018 and 2017, respectively.  Royalty: The Company is entitled to royalty payments from Biosense Webster, payable quarterly based on net revenues from sales of the co-developed catheters. Royalty revenue from the co-developed catheters represented 10% and 11% of revenue for the three months ended March 31, 2018 and 2017, respectively. Other Recurring Revenue : Other recurring revenue includes revenue from software licenses, product maintenance plans, and other post warranty maintenance. Revenue from services and license fees is deferred and amortized over the service or license fee period, which is typically one year. Revenue related to services performed on a time-and-materials basis is recognized when performed. Other recurring revenue represented 53% and 46% of revenue for the three months ended March 31, 2018 and 2017, respectively .     Three months ended March 31,  2018 2017  Systems $ 17,275 $ 218,895  Disposables, service and accessories 6,954,357 6,758,777  Total revenue $ 6,971,632 $ 6,977,672 Transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not yet been recognized. A significant portion of this amount relates to the Company's systems contracts and obligations that will be recognized as revenue in future periods. These obligations are generally satisfied within two years after contract inception but may occasionally extend longer. Transaction price representing revenue to be earned on remaining performance obligations on system contracts was approximately $1.4 million as of March 31, 2018 . Performance obligations arising from contracts for disposables, royalty and service are generally expected to be satisfied within one year after entering into the contract. The following information summarizes the Company’s contract assets and liabilities :    March 31, December 31,  2018 2017  Contract Assets - Unbilled Receivables $ 55,341 $ 2,917   Product shipped, revenue deferred $ 940,665 $ 941,724  Deferred service and license fees 6,756,049 5,372,908  Total deferred revenue 7,696,714 6,314,632  Less: Long-term deferred revenue (560,649) (611,863)  Total current deferred revenue $ 7,136,065 $ 5,702,769   The Company invoices its customers based on the billing schedules in its sales arrangements. Contract assets primarily represent the differen ce between the revenue that was earned but not billed on service contracts and revenue from system contracts that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Deferred revenue is primarily related to service contracts, for which the service fees are billed up-front, generally qu arterly or annually, and for amounts billed in advance for system contracts for which some performance obligatio ns remain outstanding. For service contracts, the associated deferred revenue is generally recognized ratably over the service period. For system contracts, the associated deferred revenue is recognized when the remaining performa nce obligations are satisfied. The Comp any did not have any impairment losses on its contract assets for the periods presented. Revenue recognized for the three months ended March 31, 2018 and 2017, that was included in the deferred revenue balance at the beginning of each reporting period was $2 ,643,425 and $2 ,664,371 , respectively .  Assets Recognized from the Costs to Obtain a Contract with a Customer The Company has determined that sales incentive programs for the Company’s sales team meet the requirements to be capitalized as the Company expects to generate future economic benefits from the related revenue generating contracts after the initial capital sales transaction. The costs capitalized as contract acquisition costs included in prepaid expenses and other current assets, in the Company’s balance sheet was $0.4 million as of March 31, 2018. The Company did not incur any impairment losses during any of the periods presented. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred. Share-Based Compensation The Company accounts for its grants of stock options, stock appreciation rights, restricted shares, and restricted stock units and for its employee stock purchase plan in accordance with the provisions of general accounting principles for share-based payments. These accounting principles require the determination of the fair value of the share-based compensation at the grant date and the recognition of the related expense over the period in which the share-based compensation vests. The Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The resulting compensation expense is recognized over the requisite service period, which is generally four years. Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the fair market value to expense over the service period. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives. Net Earnings (Loss) per Common Share (“EPS”) Basic net income (loss) per share is computed by dividing net income (loss) attributable to common shareholders by the number of common shares outstanding during the period. In periods where there is net income, we apply the two-class method to calculate basic and diluted net income (loss) per share of common stock, as our Convertible Preferred Stock is a participating security. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. In periods where there is a net loss, the two-class method of computing earnings per share does not apply as our Convertible Preferred Stock does not contractually participate in our losses. We compute diluted net income (loss) per common share using net income (loss) as the “control number” in determining whether potential common shares are dilutive, after giving consideration to all potentially dilutive common shares, including stock options, warrants, unvested restricted stock units outstanding during the period and potential issuance of stock upon the conversion of our Convertible Preferred Stock issued and outstanding during the period, except where the effect of such securities would be antidilutive. The following table sets forth the computation of basic and diluted EPS:    Three months ended March 31,  2018 2017  Net income $ 1,435,229 $ 1,176,967  Cumulative dividend on convertible preferred stock (353,589) (363,188)  Net income attributable to convertible preferred stockholders $ (610,280) $ (509,323)  Net income attributable to common stockholders 471,360 304,456  Shares used for basic EPS-weighted average shares 30,957,648 22,318,000  Restricted Stock Units 292,891 13,683  Warrants 1,872,059 —  Weighted average number of common shares and equivalents: 33,122,598 22,331,683  Basic EPS $ 0.02 $ 0.01  Diluted EPS $ 0.01 $ 0.01  The following potential common shares were excluded from diluted EPS for the three months ended March 31, 2018 as they were antidilutive: 1,236,445 stock options and stock appreciation rights, 280,560 restricted stock units, and 1,077,255 warrants. The following potential common shares were excluded from diluted EPS for the three months ended March 31, 2017 as they were antidilutive: 665,477 stock options and stock appreciation rights, 671,929 restricted stock units, and 38,887,708 warrants. As of March 31, 2018, the Company had 1,236,445 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $3.27 per share , 2,949,314 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $2.32 per share, 40,081,485 shares of common stock issuable upon the conversion of Series A Convertible Preferred Stock and accumulated dividends, and 573,451 shares of unvested restricted share units. Reclassifications In 2018, we adjusted our operati ng expense categories to improve our alignment with common industry reporting practice, and as a result, certain amounts in prior periods have been reclassified to conform to the current period presentation. Regulatory and clinical research expense s were previously included in General and Administrative expense and have been reclassified to Research and Development. International training expense was previously included in General and Administrative expense and has been reclassified to Sales and Marketing expense. These reclassifications had no effect on reported income or losses.  Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, “Leases (ASC 842),” which sets out the principles for the recognition, measurement, presentation, and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is effective for interim and annual periods beginning after December 31, 2018 (January 1, 2019 for the Company), with early adoption permitted. The Company is in the process of evaluating the impact of this accounting standard update.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2018
Inventories [Abstract]
Inventories	3. Inventories Inventories consist of the following:    March 31, 2018 December 31, 2017   Raw materials $ 2,578,473 $ 2,528,270  Work in process 197,820 4,836  Finished goods 2,779,669 2,515,637  Reserve for obsolescence (4,109,388) (3,901,772)  Total inventory $ 1,446,574 $ 1,146,971 

Prepaid Expenses And Other Curr

Prepaid Expenses And Other Current Assets	3 Months Ended
	Mar. 31, 2018
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid Expenses And Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following:       March 31, 2018 December 31, 2017   Prepaid expenses $ 458,547 $ 575,501  Prepaid commissions 384,879 -  Deferred financing costs - 24,658  Deposits 180,848 194,358  Total prepaid expenses and other assets 1,024,274 794,517  Less: Noncurrent prepaid expenses and other assets (282,199) (44,432)  Total current prepaid expenses and other assets $ 742,075 $ 750,085         Effective with the January 1, 2018 adoption of ASC 606, the Company determined that sales commissions paid in connection with multi-year service contracts met the requirements to be capitalized as the Company expects to generate future economic benefits from the relate d revenue generating contracts. Previously, sales commissions on multi-year service contracts were expensed as incurred. The Company is amortizing this asset over the economic life of the related contracts .

Property And Equipment

Property And Equipment	3 Months Ended
	Mar. 31, 2018
Property And Equipment [Abstract]
Property And Equipment	5. Property and Equipment Property and equipment consist of the following:    March 31, December 31,  2018 2017   Equipment $ 7,259,470 $ 7,295,698  Leasehold improvements 2,592,338 2,592,339  9,851,808 9,888,037  Less: Accumulated depreciation (9,389,595) (9,295,349)  Net property and equipment $ 462,213 $ 592,688 

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2018
Intangible Assets [Abstract]
Intangible Assets	6. Intangible Assets  As of March 3 1 , 201 8 , the Company had total intangible assets of $3,143,291 . Accumulated amortization at March 3 1, 2018 , was $3,000,318.   

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2018
Accrued Liabilities [Abstract]
Accrued Liabilities	7. Accrued Liabilities Accrued liabilities consist of the following:    March 31, December 31,  2018 2017   Accrued salaries, bonus, and benefits $ 1,376,613 $ 1,641,491  Accrued rent 348,690 441,417  Accrued licenses and maintenance fees 581,691 581,672  Accrued warranties 145,172 164,365  Accrued taxes 258,964 234,668  Accrued professional services 491,894 367,072  Other 325,519 299,931  Total accrued liabilities 3,528,543 3,730,616  Less: Long term accrued liabilities (580,866) (535,369)  Total current accrued liabilities $ 2,947,677 $ 3,195,247   Our primary company facilities are located in St. Louis, Missouri where we currently lease approximately 52,000 square feet of office and 12,000 square feet of demonstration and assembly space. In the third quarter of 2013, the Company modified the existing lease agreement to terminate approximately 13,000 square feet of unimproved space. The costs associated with the termination were $515,138 and were accrued as a rent liability as of September 30, 2013. As of March 3 1, 2018 , the remaining accrued costs associated with the termination were $71,592 . In August 2016 the Company entered into an agreement to sublease approximately 11,000 square feet of office space immediately and an additional 16,000 square feet of office space beginning in January, 2017, with the term of the sublease ending on December 31, 2018. The initial costs associated with the sub lease were $69,180 , and as of March 31, 2018, the remaining accrue d costs were $19,822 .

Long-Term Debt And Credit Facil

Long-Term Debt And Credit Facilities	3 Months Ended
	Mar. 31, 2018
Long-Term Debt And Credit Facilities [Abstract]
Long-Term Debt And Credit Facilities	8. Long-Term Debt and Credit Facilities The Company has had a working capital line of credit with its primary lender, Silicon Valley Bank, since 2004. The revolving line of credit is secured by substantially all of the Company’s assets. The maximum available under the line is $5.0 million subject to the value of collateralized assets. The Company is required under the revolving line of credit to maintain its primary operating account and the majority of its cash and investment balances in accounts with its primary lender. The facility was amended on March 27, 2015, extending the maturity date to March 31, 2018. On November 7 , 2017, the Company a nd the primary lender agreed to adjust the maximum availability under the Company’s revolving line of credit from $10.0 million to $5.0 million with a pro-rata reduction in related loan costs, as well as a reduction in the interest rate floor from 7.0% to 5.75% . As of March 31, 2018, the agreement required the Company to maintain a liquidity ratio greater than 1.50 :1.00, excluding certain short term advances from the calculation, and a minimum tangible net worth of not less than (no worse than) negative $24.0 million for the quarters ended June 30, 2016, September 30, 2016, December 31, 2016, March 31, 2017, June 30, 2017, and September 30, 2017; and not less than (no worse than) negative $24.5 million for the quarters ended December 31, 2017 and March 31, 2018. As of March 31, 2018, the Company had no outstanding balance under the revolving line of credit. Draws on the line of credit are made based on the borrowing capacity one week in arrears. As of March 31, 2018, the Company had a borrowing capacity of $ 4.5 million based on the Company’s collateralized assets. The Company’s total liquidity as of March 31, 2018, was $ 16.1 million which included cash and cash equivalents of $11.6 million. As of March 31, 2018, we were in compliance with all financial covenants of this agreement and we anticipate continued compliance throughout the remainder of 2018. On April 26, 2018, the Company entered into a First Amendment to Third Amended and Restated Loan and Security Agreement with Silicon Valley Bank to extend the maturity of the revolving line of credit from March 31, 2018 to April 25, 2019. The maximum availability under the revolving line of credit remains at $5.0 million, and provides for an interest rate during a “streamline period” equal to the prime rate subject to a floor of 4.5% . A “streamline period” occurs when the Company has, for each consecutive day in the immediately preceding monthly period, maintained a liquidity ratio greater than 1.75 :1.00, and continuing so long as the stream line period has been maintained. Upon the termination of a streamline period, the Company must maintain the streamline threshold each consecutive day for one fiscal quarter, prior to entering into a subsequent streamline period. During non-streamline periods, the interest rate is the prime rate plus 1.5% , subject to a f loor of 4.5% . In addition, the amendment eliminates the tan gible net worth covenant and requires that the liquidity ratio shall at all times include not less than $1.5 million of the Borrower’s unrestricted cash and cash equivalents maintained at the Bank prior to giving effect to any advance.

Convertible Preferred Stock And

Convertible Preferred Stock And Stockholders' Equity	3 Months Ended
	Mar. 31, 2018
Convertible Preferred Stock And Stockholders' Equity [Abstract]
Convertible Preferred Stock And Stockholders' Equity	9 . Convertible Preferred Stock and Stockholders’ Equity The holders of common stock are entitled to one vote for each share held and to receive dividends whenever funds are legally available and when declared by the Board of Directors subject to the rights of holders of all classes of stock having priority rights as dividends and the conditions of the revolving line of credit agreement . No dividends have been declared or paid as of March 31, 2018. Convertible Preferred Stock and Warrants In September, 2016, the Company issued 24,000 shares of Series A Convertible Preferred Stock, par value $0.001 with a stated value of $1,000 per share which are convertible into shares of the Company’s common stock at an initial conversion rate of $0.65 per share and (ii) warrants to purchase an aggregate of 36,923,078 shares of common stock. The convertible preferred shares are entitled to vote on an as-converted basis with the common stock, subject to specified beneficial ownership issuance limitations. The convertible preferred shares bear dividends at a rate of six percent ( 6% ) per annum, which are cumulative and accrue daily from the date of issuance on the $1,000 stated value. Such dividends will not be paid in cash except in connection with any liquidation, dissolution or winding up of the Company or any redemption of the convertible preferred shares. Each holder of convertible preferred shares has the right to require us to redeem such holder’s convertible preferred shares upon the occurrence of specified events, which include certain business combinations, the sale of all or substantially all of the Company’s assets, or the sale of more than 50% of the outstanding shares of the Company’s common stock. In addition, the Company has the right to redeem the convertible preferred shares in the event of a defined change of control. The convertible preferred shares rank senior to our common stock as to distributions and payments upon the liquidation, dissolution, and winding up of the Company. Since the convertible preferred shares are subject to conditions for redemption that are outside the Company’s control, the convertible preferred shares are presently reported in the mezzanine section of the balance sheet. The warrants issued in conjunction with the convertible preferred stock have an exercise price equal to $0.70 per share subject to adjustments as provided under the terms of the warrants. The warrants are exercisable through September 29, 2021, subject to specified beneficial ownership issuance limitations. Prior to their modification in February, 2018, the warrants were puttable upon the occurrence of certain events outside of the Company’s control, and were classified as liabilities under ASC 480-10. The calculated fair value of the warrants was periodically re-measured with any changes in value recognized in “Other income (expense)” in the Statements of Operations. See Note 10 for additional details. The warrants were modified on February 28, 2018 to allow for a reduction in the exercise price from $0.70 per share to $0.28 per share for a period between March 1, 2018 and March 5, 2018. Additionally, the beneficial ownership limitation related to the warrants was modified and the right of holders to require the Company to redeem their SPA Warrants in exchange for cash in certain circumstances was eliminated. Following these modif ications, the warrants were no longer subject to liability accounting and were reclassified to equity. During the restricted exercise period, Stereotaxis received exercise notices for 35,791,927 warrants and received an aggregate of $10.0 million in cash from the warrant exercise. As a result of these transactions, total stockholders ’ equity increased by $27 million and common shares outstanding increased by 35,791,927 shares. Stock Award Plans The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation. In July 2012, the Compensation Committee of the Board of Directors adopted the 2012 S tock I ncentive P la n (the “Plan”) which was subsequently approved by the Company’s shareholders. This plan replaced the 2002 Stock Incentive Plan which expired on March 25, 2012. On June 5, 2013, June 10, 2014, May 24, 2016, and May 23, 2017, the shareholders approved amendments to the Plan, which were previously approved and adopted by the Compensation Committee of the Board of Directors of the Company. Under each of the amendments on June 5, 2013 and June 10, 2014, the number of shares authorized for issuance under the Plan was increased by one million shares. The amendment on May 24, 2016 increased the number of shares authorized for issuance under the Plan by 1.5 million shares, and t he amendment on May 23, 2017 increased the number of shares authorized for issuance under the Plan by 4.0 million shares. At March 3 1 , 201 8 , the Company had 4,564,502 remaining shares of the Company’s common stock to provide for current and future grants under its various equity plans. At March 3 1 , 201 8 , the total compensation cost related to options, stock appreciation rights , and non-vested stock granted to employees under the Company’s stock award plans but not yet recognized was approximately $1.0 million . This cost will be amortized over a period of up to four years over the underlying estimated service periods and will be adjusted for subsequent changes in actual forfeitures and anticipated vesting periods. A summary of the option and stock appreciat ion rights activity for the three month period ended March 31 , 201 8 is as follows:    Number of Options/SARs Range of Exercise Price Weighted Average Exercise Price per Share   Outstanding, December 31, 2017 413,301 $0.62 - $54.90 $9.04  Granted 858,500 $0.74 - $0.83 $0.74  Exercised - - -  Forfeited (35,356) $2.15 - $35.20 $9.14  Outstanding, March 31, 2018 1,236,445 $0.62 - $54.90 $3.27        A summary of the restricted stock unit activity for the three month period ended March 3 1 , 201 8 is as follows:    Number of Restricted Stock Units Weighted Average Grant Date Fair Value per Unit   Outstanding, December 31, 2017 680,363 $1.11  Granted 212,000 $0.84  Vested (285,662) $1.36  Forfeited (33,250) $1.26  Outstanding, March 31, 2018 573,451 $0.88 

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2018
Fair Value Measurements [Abstract]
Fair Value Measurements	10 . Fair Value Measurements  The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below: Level 1: Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.  Level 2: Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market.  Level 3: Values are generated from model-based techniques that use significant assumptions not observable in the market.  The following table sets forth the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. As required by the Fair Value Measurements and Disclosures topic of the Accounting Standards Codification, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.       Fair Value Measurement Using  Total Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3)  Liabilities at March 31, 2018:  Warrants issued May 2012 $ — $ — $ — $ —  Warrants issued August 2013 — — — —  Warrants issued September 2016 — — — —  Total liabilities at fair value: $ — $ — $ — $ —  Liabilities at December 31, 2017:  Warrants issued May 2012 $ — $ — $ — $ —  Warrants issued August 2013 5,746 — — 5,746  Warrants issued September 2016 19,569,231 — — 19,569,231  Total liabilities at fair value: $ 19,574,977 $ — $ — $ 19,574,977  Level 1 The Company does not have any financial assets or liabilities classified as Level 1. Level 2 The Company does not have any financial assets or liabilities classified as Level 2. Level 3 In conjunction with the Company’s May 2012, August 2013 and September 2016 financing transactions, the Company issued warrants to purchase shares of the Company’s common stock. Due to the provisions included in the warrant agreements at the time of issuance , the warrants did not meet the exemptions for equity classification a nd as such, the Company accounted for these warrants as derivative instruments. The calculated fair value of the warrants issued in conjunction with the May 2012 and August 2013 financing transactions is classified as a liability and is periodically re-measured with any changes in value recognized in “Other income (expense)” in the Statements of Operations. As detailed in Note 9, t he remaining warrants from the September 2016 transaction were modified on February 28, 2018 and reclassified to equity. The remaining warrants from the May 2012 transaction (PIPE Warrants) expire in May 2018 and were revalued as of March 31, 2018 using the following assumptions: 1) volatility of 50.37% ; 2) risk-free interest rate of 1.63% ; and 3) a closing stock price of $0.66 . The remaining warrants from the August 2013 transaction (Exchange Warrants) expire in November 2018 and were revalued as of March 31, 2018 using the following assumptions: 1) volatility of 68.30% ; 2) risk-free interest rate of 1.93% ; and 3) a closing stock price of $0.66 . The significant unobservable input used in the fair value measurement of the Company’s warrants is volatility. Significant increases (decreases) in the volatility in isolation would result in significantly higher (lower) liability fair value measurements.  The following table sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the three month period ended March 3 1, 2018 :      Warrants issued May 2012 Warrants issued August 2013 Warrants issued September 2016 Total Liabilities  Balance at beginning of period $ - $ 5,746 $ 19,569,231 $ 19,574,977  Issues - - - -  Reclassifications - - (16,984,616) (16,984,616)  Settlements - - - -  Revaluation - (5,746) (2,584,615) (2,590,361)  Balance at end of period $ - $ - $ - $ -  The Company currently does not have derivative instruments to manage its exposure to currency fluctuations or other business risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. All derivative financial instruments are recognized in the balance sheet at fair value.

Product Warranty Provisions

Product Warranty Provisions	3 Months Ended
	Mar. 31, 2018
Product Warranty Provisions [Abstract]
Product Warranty Provisions	11 . Product Warranty Provisions  The Company’s standard policy is to warrant all Niobe , Odyssey, and Vdrive systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability as appropriate.  Accrued warranty, which is included in other accrued liabilities, consists of the following:     March 31, 2018 December 31, 2017  Warranty accrual, beginning of the fiscal period $ 164,365 $ 222,845  Accrual adjustment for product warranty (2,640) 32,679  Payments made (16,553) (91,159)  Warranty accrual, end of the fiscal period $ 145,172 $ 164,365 

Commitments And Contingencies

Commitments And Contingencies	3 Months Ended
	Mar. 31, 2018
Commitments And Contingencies [Abstract]
Commitments And Contingencies	12 . Commitments and Contingencies  The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	13 . Subsequent Events On April 26, 2018, the Company entered into a First Amendment to Third Amended and Restated Loan and Security Agreement with Silicon Valley Bank to extend the maturity of the revolving line of credit from March 31, 2018 to April 25, 2019. The maximum availability under the revolving line of credit remains at $5.0 million, and provides for an interest rate during a “streamline period” equal to the prime rate subject to a floor of 4.5% . A “streamline period” occurs when the Company has, for each consecutive day in the immediately preceding monthly period, maintained a liquidity ratio greater than 1.75 :1.00, and continuing so long as the stream line period has been maintained. Upon the termination of a streamline period, the Company must maintain the streamline threshold each consecutive day for one fiscal quarter, prior to entering into a subsequent streamline period. During non-streamline periods, the interest rate is the prime rate plus 1.5% , subject to a f loor of 4.5% . In addition, the amendment eliminates the tan gible net worth covenant and requires that the liquidity ratio shall at all times include not less than $1.5 million of the Borrower’s unrestricted cash and cash equivalents maintained at the Bank prior to giving effect to any advance . 

Summary Of Significant Accoun19

Summary Of Significant Accounting Policies (Policy)	3 Months Ended
	Mar. 31, 2018
Summary Of Significant Accounting Policies [Abstract]
Basis Of Presentation	Basis of Presentation The accompanying unaudited financial statements of Stereotaxis, Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and the instructions to Form 10-Q. Accordingly, they do not include all the disclosures required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, they include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Operating results for th e three month period ended March 3 1 , 201 8 are not necessarily indicative of the results that may be expected for the year ended December 31, 201 8 or for future operating periods. These interim financial statements and the related notes should be read in conjunction with the annual financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended Dec ember 31, 2017 as filed with the Securities and Exchange Commission (SEC) on Marc h 20, 201 8 .
Financial Instruments	Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable , and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. The Company measures certain financial assets and liabilities, including warrants, at fair value on a recurring basis. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 10 for additional details.
Revenue And Costs Of Revenue	Revenue and Costs of Revenue The Company adopted ASC 606, Revenue from Contracts with Customers, on January 1, 2018 using the modified retrospective method. As part of the Company's adoption of ASC 606, the Company elected to use the following practical expedients (i) applying the modified retrospective method only to open contracts as of December 31, 2017; (ii) not to adjust the promised amount of consideration for the effects of a significant financing component when the Company expects, at contract inception, that the period between the Company's transfer of a promised product or service to a customer and when the customer pays for that product or service will be one year or less; (iii) to expense costs as incurred for costs to obtain a contract when the amortization period would have bee n one year or less; and (iv) not to assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer. Upon adoption of the new revenue guidance, the Company recorded a cumulative-effect reduction to accumulated deficit of $0.3 million on January 1, 2018 relating primarily to the deferral of previously expensed costs to obtain a contract. The Company capitalized sales commissions paid in connection with multi-year service contracts and is amortizing such asset over the economic life of those contracts. Previously, sales commissions on multi-year service contracts were expensed as incurred. The impact of this change on operating expenses in any given period will depend, in part, on the amount of such commissions incurred and capitalized in relation to the amount of ongoing amortization expense. In the first quarter of 2018, the Company recorded $0.1 million less in commission expense as a result of adopting the new standard. The Company did not otherwise experience significant changes in the timing or method of revenue recognition for any of its material revenue streams. We generate revenue from initial capital sales of systems as well as recurring revenue from the sale of our proprietary disposable devices, from royalties paid to the Company on the sale by Biosense Webster of co-developed catheters, and from other recurring revenue including ongoin g license and service contracts. We account for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We record our revenue based on consideration specified in the contract with each customer, net of any taxes collected from customers that are remitted to government authorities. For contracts containing multiple products and services the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company recognizes revenues as the performance obligations are satisfied by transferring control of the product or service to a customer. For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services and market conditions. The Company regularly reviews standalone selling price s and updates these estimates as necessary . Systems: Contracts related to the sale of systems typically contain separate obligations for the delivery of system(s), installation and an implied obligation to provide software enhancements if and when available for one year following installation. Revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. Revenue from the implied obligation to deliver software enhancements if and when available is recognized ratably over the first year following installation of the system as the customer receives the right to software updates throughout the period and is included in Other Recurring Revenue. The Company’s system contracts generally do not provide a right of return. Systems are generally covered by a one-year assurance type warranty; warranty costs were not material for the periods presented. Revenue from system delivery and installation represented less than 1% and 3% of revenue for the three months ended March 31, 2018 and 2017, respectively. Disposables: Revenue from sales of disposable products is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but can also occur at the time of delivery depending on the customer arrangement. Disposable products are covered by a n assurance type warranty that provides for the return of defective products. Warranty costs were not material for the periods presented. Disposable revenue represented 37% and 40% of revenue for the three months ended March 31, 2018 and 2017, respectively.  Royalty: The Company is entitled to royalty payments from Biosense Webster, payable quarterly based on net revenues from sales of the co-developed catheters. Royalty revenue from the co-developed catheters represented 10% and 11% of revenue for the three months ended March 31, 2018 and 2017, respectively. Other Recurring Revenue : Other recurring revenue includes revenue from software licenses, product maintenance plans, and other post warranty maintenance. Revenue from services and license fees is deferred and amortized over the service or license fee period, which is typically one year. Revenue related to services performed on a time-and-materials basis is recognized when performed. Other recurring revenue represented 53% and 46% of revenue for the three months ended March 31, 2018 and 2017, respectively .     Three months ended March 31,  2018 2017  Systems $ 17,275 $ 218,895  Disposables, service and accessories 6,954,357 6,758,777  Total revenue $ 6,971,632 $ 6,977,672 Transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not yet been recognized. A significant portion of this amount relates to the Company's systems contracts and obligations that will be recognized as revenue in future periods. These obligations are generally satisfied within two years after contract inception but may occasionally extend longer. Transaction price representing revenue to be earned on remaining performance obligations on system contracts was approximately $1.4 million as of March 31, 2018 . Performance obligations arising from contracts for disposables, royalty and service are generally expected to be satisfied within one year after entering into the contract. The following information summarizes the Company’s contract assets and liabilities :    March 31, December 31,  2018 2017  Contract Assets - Unbilled Receivables $ 55,341 $ 2,917   Product shipped, revenue deferred $ 940,665 $ 941,724  Deferred service and license fees 6,756,049 5,372,908  Total deferred revenue 7,696,714 6,314,632  Less: Long-term deferred revenue (560,649) (611,863)  Total current deferred revenue $ 7,136,065 $ 5,702,769   The Company invoices its customers based on the billing schedules in its sales arrangements. Contract assets primarily represent the differen ce between the revenue that was earned but not billed on service contracts and revenue from system contracts that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Deferred revenue is primarily related to service contracts, for which the service fees are billed up-front, generally qu arterly or annually, and for amounts billed in advance for system contracts for which some performance obligatio ns remain outstanding. For service contracts, the associated deferred revenue is generally recognized ratably over the service period. For system contracts, the associated deferred revenue is recognized when the remaining performa nce obligations are satisfied. The Comp any did not have any impairment losses on its contract assets for the periods presented. Revenue recognized for the three months ended March 31, 2018 and 2017, that was included in the deferred revenue balance at the beginning of each reporting period was $2 ,643,425 and $2 ,664,371 , respectively . 
Assets Recognized From The Cost To Obtain A Contract With A Customer	Assets Recognized from the Costs to Obtain a Contract with a Customer The Company has determined that sales incentive programs for the Company’s sales team meet the requirements to be capitalized as the Company expects to generate future economic benefits from the related revenue generating contracts after the initial capital sales transaction. The costs capitalized as contract acquisition costs included in prepaid expenses and other current assets, in the Company’s balance sheet was $0.4 million as of March 31, 2018. The Company did not incur any impairment losses during any of the periods presented. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.
Share-Based Compensation	Share-Based Compensation The Company accounts for its grants of stock options, stock appreciation rights, restricted shares, and restricted stock units and for its employee stock purchase plan in accordance with the provisions of general accounting principles for share-based payments. These accounting principles require the determination of the fair value of the share-based compensation at the grant date and the recognition of the related expense over the period in which the share-based compensation vests. The Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The resulting compensation expense is recognized over the requisite service period, which is generally four years. Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the fair market value to expense over the service period. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives.
Net Earnings (Loss) per Common Share	Net Earnings (Loss) per Common Share (“EPS”) Basic net income (loss) per share is computed by dividing net income (loss) attributable to common shareholders by the number of common shares outstanding during the period. In periods where there is net income, we apply the two-class method to calculate basic and diluted net income (loss) per share of common stock, as our Convertible Preferred Stock is a participating security. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. In periods where there is a net loss, the two-class method of computing earnings per share does not apply as our Convertible Preferred Stock does not contractually participate in our losses. We compute diluted net income (loss) per common share using net income (loss) as the “control number” in determining whether potential common shares are dilutive, after giving consideration to all potentially dilutive common shares, including stock options, warrants, unvested restricted stock units outstanding during the period and potential issuance of stock upon the conversion of our Convertible Preferred Stock issued and outstanding during the period, except where the effect of such securities would be antidilutive. The following table sets forth the computation of basic and diluted EPS:    Three months ended March 31,  2018 2017  Net income $ 1,435,229 $ 1,176,967  Cumulative dividend on convertible preferred stock (353,589) (363,188)  Net income attributable to convertible preferred stockholders $ (610,280) $ (509,323)  Net income attributable to common stockholders 471,360 304,456  Shares used for basic EPS-weighted average shares 30,957,648 22,318,000  Restricted Stock Units 292,891 13,683  Warrants 1,872,059 —  Weighted average number of common shares and equivalents: 33,122,598 22,331,683  Basic EPS $ 0.02 $ 0.01  Diluted EPS $ 0.01 $ 0.01  The following potential common shares were excluded from diluted EPS for the three months ended March 31, 2018 as they were antidilutive: 1,236,445 stock options and stock appreciation rights, 280,560 restricted stock units, and 1,077,255 warrants. The following potential common shares were excluded from diluted EPS for the three months ended March 31, 2017 as they were antidilutive: 665,477 stock options and stock appreciation rights, 671,929 restricted stock units, and 38,887,708 warrants. As of March 31, 2018, the Company had 1,236,445 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $3.27 per share , 2,949,314 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $2.32 per share, 40,081,485 shares of common stock issuable upon the conversion of Series A Convertible Preferred Stock and accumulated dividends, and 573,451 shares of unvested restricted share units.
Reclassifications	Reclassifications In 2018, we adjusted our operati ng expense categories to improve our alignment with common industry reporting practice, and as a result, certain amounts in prior periods have been reclassified to conform to the current period presentation. Regulatory and clinical research expense s were previously included in General and Administrative expense and have been reclassified to Research and Development. International training expense was previously included in General and Administrative expense and has been reclassified to Sales and Marketing expense. These reclassifications had no effect on reported income or losses. 
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, “Leases (ASC 842),” which sets out the principles for the recognition, measurement, presentation, and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is effective for interim and annual periods beginning after December 31, 2018 (January 1, 2019 for the Company), with early adoption permitted. The Company is in the process of evaluating the impact of this accounting standard update.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2018
Summary Of Significant Accounting Policies [Abstract]
Schedule Of Revenue Disaggregated By Type	  Three months ended March 31,  2018 2017  Systems $ 17,275 $ 218,895  Disposables, service and accessories 6,954,357 6,758,777  Total revenue $ 6,971,632 $ 6,977,672 
Summary Of Contract Assets And Liabilities	  March 31, December 31,  2018 2017  Contract Assets - Unbilled Receivables $ 55,341 $ 2,917   Product shipped, revenue deferred $ 940,665 $ 941,724  Deferred service and license fees 6,756,049 5,372,908  Total deferred revenue 7,696,714 6,314,632  Less: Long-term deferred revenue (560,649) (611,863)  Total current deferred revenue $ 7,136,065 $ 5,702,769  
Computation Of Basic And Diluted EPS	  Three months ended March 31,  2018 2017  Net income $ 1,435,229 $ 1,176,967  Cumulative dividend on convertible preferred stock (353,589) (363,188)  Net income attributable to convertible preferred stockholders $ (610,280) $ (509,323)  Net income attributable to common stockholders 471,360 304,456  Shares used for basic EPS-weighted average shares 30,957,648 22,318,000  Restricted Stock Units 292,891 13,683  Warrants 1,872,059 —  Weighted average number of common shares and equivalents: 33,122,598 22,331,683  Basic EPS $ 0.02 $ 0.01  Diluted EPS $ 0.01 $ 0.01 

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2018
Inventories [Abstract]
Schedule Of Inventories	  March 31, 2018 December 31, 2017   Raw materials $ 2,578,473 $ 2,528,270  Work in process 197,820 4,836  Finished goods 2,779,669 2,515,637  Reserve for obsolescence (4,109,388) (3,901,772)  Total inventory $ 1,446,574 $ 1,146,971 

Prepaid Expenses And Other Cu22

Prepaid Expenses And Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2018
Prepaid Expenses And Other Current Assets [Abstract]
Schedule Of Prepaid Expenses And Other Current Assets	   March 31, 2018 December 31, 2017   Prepaid expenses $ 458,547 $ 575,501  Prepaid commissions 384,879 -  Deferred financing costs - 24,658  Deposits 180,848 194,358  Total prepaid expenses and other assets 1,024,274 794,517  Less: Noncurrent prepaid expenses and other assets (282,199) (44,432)  Total current prepaid expenses and other assets $ 742,075 $ 750,085 

Property And Equipment (Tables)

Property And Equipment (Tables)	3 Months Ended
	Mar. 31, 2018
Property And Equipment [Abstract]
Schedule Of Property And Equipment	  March 31, December 31,  2018 2017   Equipment $ 7,259,470 $ 7,295,698  Leasehold improvements 2,592,338 2,592,339  9,851,808 9,888,037  Less: Accumulated depreciation (9,389,595) (9,295,349)  Net property and equipment $ 462,213 $ 592,688 

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2018
Accrued Liabilities [Abstract]
Schedule Of Accrued Liabilities	  March 31, December 31,  2018 2017   Accrued salaries, bonus, and benefits $ 1,376,613 $ 1,641,491  Accrued rent 348,690 441,417  Accrued licenses and maintenance fees 581,691 581,672  Accrued warranties 145,172 164,365  Accrued taxes 258,964 234,668  Accrued professional services 491,894 367,072  Other 325,519 299,931  Total accrued liabilities 3,528,543 3,730,616  Less: Long term accrued liabilities (580,866) (535,369)  Total current accrued liabilities $ 2,947,677 $ 3,195,247 

Convertible Preferred Stock A25

Convertible Preferred Stock And Stockholder's Equity (Tables)	3 Months Ended
	Mar. 31, 2018
Convertible Preferred Stock And Stockholders' Equity [Abstract]
Summary Of Option And Stock Appreciation Rights Activity	  Number of Options/SARs Range of Exercise Price Weighted Average Exercise Price per Share   Outstanding, December 31, 2017 413,301 $0.62 - $54.90 $9.04  Granted 858,500 $0.74 - $0.83 $0.74  Exercised - - -  Forfeited (35,356) $2.15 - $35.20 $9.14  Outstanding, March 31, 2018 1,236,445 $0.62 - $54.90 $3.27 
Summary Of Restricted Stock Unit Activity	  Number of Restricted Stock Units Weighted Average Grant Date Fair Value per Unit   Outstanding, December 31, 2017 680,363 $1.11  Granted 212,000 $0.84  Vested (285,662) $1.36  Forfeited (33,250) $1.26  Outstanding, March 31, 2018 573,451 $0.88 

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2018
Fair Value Measurements [Abstract]
Assets And Liabilities Measured At Fair Value On Recurring Basis By Level	  Fair Value Measurement Using  Total Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3)  Liabilities at March 31, 2018:  Warrants issued May 2012 $ — $ — $ — $ —  Warrants issued August 2013 — — — —  Warrants issued September 2016 — — — —  Total liabilities at fair value: $ — $ — $ — $ —  Liabilities at December 31, 2017:  Warrants issued May 2012 $ — $ — $ — $ —  Warrants issued August 2013 5,746 — — 5,746  Warrants issued September 2016 19,569,231 — — 19,569,231  Total liabilities at fair value: $ 19,574,977 $ — $ — $ 19,574,977 
Summary Of Changes In Fair Value Of Level 3 Financial Liabilities	  Warrants issued May 2012 Warrants issued August 2013 Warrants issued September 2016 Total Liabilities  Balance at beginning of period $ - $ 5,746 $ 19,569,231 $ 19,574,977  Issues - - - -  Reclassifications - - (16,984,616) (16,984,616)  Settlements - - - -  Revaluation - (5,746) (2,584,615) (2,590,361)  Balance at end of period $ - $ - $ - $ - 

Product Warranty Provisions (Ta

Product Warranty Provisions (Tables)	3 Months Ended
	Mar. 31, 2018
Product Warranty Provisions [Abstract]
Schedule Of Accrued Warranty	  March 31, 2018 December 31, 2017  Warranty accrual, beginning of the fiscal period $ 164,365 $ 222,845  Accrual adjustment for product warranty (2,640) 32,679  Payments made (16,553) (91,159)  Warranty accrual, end of the fiscal period $ 145,172 $ 164,365 

Summary Of Significant Accoun28

Summary Of Significant Accounting Policies (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 05, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining performance obligation	$ 1,400,000
Revenue recognized	2,643,425	$ 2,664,371
Capitalized contract costs	400,000
Exercise price of warrants			$ 0.28		$ 0.70
Revenues	6,971,632	$ 6,977,672
Accounting Standards Update 2014-09 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Effect on accumulated deficit				$ 300,000
Accounting Standards Update 2014-09 [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Effect on income	$ 100,000
Stock Options And Stock Appreciation Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, requisite service period	4 years
Options and stock appreciation rights outstanding	1,236,445			413,301
Weighted average exercise price	$ 3.27			$ 9.04
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issuable upon exercise	2,949,314
Exercise price of warrants	$ 2.32
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested restricted shares	573,451			680,363
Stock Options And Stock Appreciation Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	1,236,445	665,477
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	280,560	671,929
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	1,077,255	38,887,708
Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issuable upon exercise	40,081,485
Systems [Member] | Revenue from Contract with Customer [Member] | Customer Concentration Risk [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Revenues percentage	1.00%	3.00%
Disposables [Member] | Revenue from Contract with Customer [Member] | Customer Concentration Risk [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Revenues percentage	37.00%	40.00%
Royalty [Member] | Revenue from Contract with Customer [Member] | Customer Concentration Risk [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Revenues percentage	10.00%	11.00%
Other Recurring Revenue [Member] | Revenue from Contract with Customer [Member] | Customer Concentration Risk [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Revenues percentage	53.00%	46.00%

Summary Of Significant Accoun29

Summary Of Significant Accounting Policies (Schedule Of Revenue Disaggregated By Type) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disaggregation of Revenue [Line Items]
Revenue	$ 6,971,632	$ 6,977,672
Systems [Member]
Disaggregation of Revenue [Line Items]
Revenue	17,275	218,895
Disposables, Service And Accessories [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 6,954,357	$ 6,758,777

Summary Of Significant Accoun30

Summary Of Significant Accounting Policies (Summary Of Contract Assets And Liabilities) (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Contract Assets	$ 55,341	$ 2,917
Total deferred revenue	7,696,714	6,314,632
Less: Long-term deferred revenue	(560,649)	(611,863)
Total current deferred revenue	7,136,065	5,702,769
Product [Member]
Disaggregation of Revenue [Line Items]
Total deferred revenue	940,665	941,724
Service And License Fees [Member]
Disaggregation of Revenue [Line Items]
Total deferred revenue	$ 6,756,049	$ 5,372,908

Summary Of Significant Accoun31

Summary Of Significant Accounting Policies (Computation Of Basic And Diluted EPS) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Summary Of Significant Accounting Policies [Abstract]
Net income	$ 1,435,229	$ 1,176,967
Cumulative dividend on convertible preferred stock	(353,589)	(363,188)
Net income attributable to convertible preferred stockholders	(610,280)	(509,323)
Net income attributable to common stockholders	$ 471,360	$ 304,456
Shares used for basic EPS-weighted average shares	30,957,648	22,318,000
Effect of diluted securities: Restricted stock units	292,891	13,683
Effect of diluted securities: Warrants	1,872,059
Weighted average number of common shares and equivalents:	33,122,598	22,331,683
Basic EPS	$ 0.02	$ 0.01
Diluted EPS	$ 0.01	$ 0.01

Inventories (Details)

Inventories (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Inventories [Abstract]
Raw materials	$ 2,578,473	$ 2,528,270
Work in process	197,820	4,836
Finished goods	2,779,669	2,515,637
Reserve for obsolescence	(4,109,388)	(3,901,772)
Total inventory	$ 1,446,574	$ 1,146,971

Prepaid Expenses And Other Cu33

Prepaid Expenses And Other Current Assets (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid expenses	$ 458,547	$ 575,501
Prepaid commissions	384,879
Deferred financing costs		24,658
Deposits	180,848	194,358
Total prepaid expenses and other assets	1,024,274	794,517
Less: Noncurrent prepaid expenses and other assets	(282,199)	(44,432)
Total current prepaid expenses and other assets	$ 742,075	$ 750,085

Property And Equipment (Details

Property And Equipment (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 9,851,808	$ 9,888,037
Less: Accumulated depreciation	(9,389,595)	(9,295,349)
Net property and equipment	462,213	592,688
Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	7,259,470	7,295,698
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 2,592,338	$ 2,592,339

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Intangible Assets [Abstract]
Total intangible assets	$ 3,143,291
Accumulated amortization	3,000,318
Amortization expense	$ 16,497	$ 49,831

Accrued Liabilities (Narrative)

Accrued Liabilities (Narrative) (Details)	Mar. 31, 2018USD ($)ft²	Dec. 31, 2017USD ($)	Jan. 31, 2017USD ($)ft²	Aug. 31, 2016ft²	Sep. 30, 2013USD ($)ft²
Real Estate [Line Items]
Accrued costs of rent liability | $	$ 348,690	$ 441,417
Office [Member]
Real Estate [Line Items]
Square feet of leased space | ft²	52,000
Demonstration And Assembly [Member]
Real Estate [Line Items]
Square feet of leased space | ft²	12,000
Unimproved [Member]
Real Estate [Line Items]
Square feet of leased space | ft²					13,000
Accrued lease termination costs remaining | $	$ 71,592
Accrued costs of rent liability | $					$ 515,138
Office Sublease [Member]
Real Estate [Line Items]
Square feet of leased space | ft²				11,000
Accrued lease termination costs remaining | $	$ 19,822
Accrued costs of rent liability | $			$ 69,180
Office Sublease, January 2017 [Member]
Real Estate [Line Items]
Square feet of leased space | ft²			16,000

Accrued Liabilities (Schedule O

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Accrued Liabilities [Abstract]
Accrued salaries, bonus, and benefits	$ 1,376,613	$ 1,641,491
Accrued rent	348,690	441,417
Accrued licenses and maintenance fees	581,691	581,672
Accrued warranties	145,172	164,365	$ 222,845
Accrued taxes	258,964	234,668
Accrued professional services	491,894	367,072
Other	325,519	299,931
Total accrued liabilities	3,528,543	3,730,616
Less: Long term accrued liabilities	(580,866)	(535,369)
Total current accrued liabilities	$ 2,947,677	$ 3,195,247

Long-Term Debt And Credit Fac38

Long-Term Debt And Credit Facilities (Narrative) (Details)	Apr. 26, 2018USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Nov. 06, 2017USD ($)
Debt Instrument [Line Items]
Minimum tangible net worth requirement, period one		$ 24,000,000
Minimum tangible net worth requirement, period two		24,500,000	$ 24,500,000
Total liquidity		16,100,000
Cash and cash equivalents		11,613,713	$ 3,686,302
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity		$ 5,000,000		$ 10,000,000
Annual interest rate		5.75%		7.00%
Line of credit facility, amount outstanding		$ 0
Line of credit facility, current borrowing capacity		4,500,000
Revolving Credit Facility [Member] | Cash and Cash Equivalents [Member]
Debt Instrument [Line Items]
Minimum tangible net worth requirement		$ 1,500,000
Revolving Credit Facility [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 5,000,000
Revolving Credit Facility [Member] | Subsequent Event [Member] | Streamline Period [Member]
Debt Instrument [Line Items]
Liquidity ratio	1.75
Line of credit interest rate	4.50%
Revolving Credit Facility [Member] | Subsequent Event [Member] | Non-Streamline Period [Member]
Debt Instrument [Line Items]
Interest rate added to prime rate	1.50%
Minimum [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Liquidity ratio		1.50
Minimum [Member] | Revolving Credit Facility [Member] | Cash and Cash Equivalents [Member]
Debt Instrument [Line Items]
Minimum tangible net worth requirement		$ 1,500,000
Minimum [Member] | Revolving Credit Facility [Member] | Subsequent Event [Member] | Streamline Period [Member]
Debt Instrument [Line Items]
Liquidity ratio	1.75
Line of credit interest rate	4.50%
Minimum [Member] | Revolving Credit Facility [Member] | Subsequent Event [Member] | Non-Streamline Period [Member]
Debt Instrument [Line Items]
Line of credit interest rate	4.50%

Convertible Preferred Stock A39

Convertible Preferred Stock And Stockholders' Equity (Narrative) (Details)	Mar. 05, 2018$ / sharesshares	May 23, 2017shares	May 24, 2016shares	Jun. 10, 2014shares	Jun. 05, 2013shares	Mar. 31, 2018USD ($)$ / sharesitemshares	Mar. 31, 2017USD ($)	Dec. 31, 2017$ / sharesshares	Dec. 31, 2016$ / sharesshares
Shareholders' Equity and Share-based Payments [Line Items]
Votes per share | item						1
Dividends declared | $						$ 0
Dividends paid | $						$ 0
Preferred stock, shares issued									24,000
Preferred stock, par value | $ / shares						$ 0.001		$ 0.001
Preferred Stock, Liquidation Preference, Value | $						$ 1,000
Preferred stock, conversion price | $ / shares						$ 0.65
Common stock issuable from warrants									36,923,078
Preferred stock dividend rate						6.00%
Preferred stock redemption, triggering event, Percent of common stock sold threshold						50.00%
Exercise price of warrants | $ / shares	$ 0.28								$ 0.70
Number of warrants exercised	35,791,927
Proceeds from warrants | $						$ 9,945,164
Equity impact of warrants exercised | $						27,000,000
Proceeds from issuance of stock, net of issuance costs | $						13,622	$ 9,336
Increase in number of shares authorized for issuance under the Plan		4,000,000	1,500,000	1,000,000	1,000,000
Total compensation cost not yet recognized | $						$ 1,000,000
Weighted average amortization period of total compensation cost not yet recognized						4 years
Remaining shares available for issuance						4,564,502
Stock Options And Stock Appreciation Rights [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options and stock appreciation rights outstanding						1,236,445		413,301
Options and stock appreciation rights exercised
Warrants [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Exercise price of warrants | $ / shares						$ 2.32
Restricted Stock Units [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Restricted shares outstanding						573,451		680,363

Convertible Preferred Stock A40

Convertible Preferred Stock And Stockholders' Equity (Summary Of Option And Stock Appreciation Rights Activity) (Details) - Stock Options And Stock Appreciation Rights [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options/SARs, Outstanding, December 31, 2017	413,301
Number of Options/SARs, Granted	858,500
Number of Options/SARs, Exercised
Number of Options/SARs, Forfeited	(35,356)
Number of Options/SARs, Outstanding, March 31, 2018	1,236,445	413,301
Weighted Average Exercise Price per Share, Outstanding, December 31, 2017	$ 9.04
Weighted Average Exercise Price per Share, Granted	0.74
Weighted Average Exercise Price per Share, Exercised
Weighted Average Exercise Price per Share, Forfeited	9.14
Weighted Average Exercise Price per Share, Outstanding, March 31, 2018	3.27	$ 9.04
$0.62 - $54.90 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit		0.62
Range of Exercise Price, Upper Limit		$ 54.90
$0.74 - $0.83 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit	0.74
Range of Exercise Price, Upper Limit	0.83
$2.15 - $32.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit	2.15
Range of Exercise Price, Upper Limit	35.20
$0.62 - $54.90 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit	0.62
Range of Exercise Price, Upper Limit	$ 54.90

Convertible Preferred Stock A41

Convertible Preferred Stock And Stockholders' Equity (Summary Of Restricted Stock Unit Activity) (Details) - Restricted Stock Units [Member]	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Restricted Stock Units, Outstanding, December 31, 2017 | shares	680,363
Number of Restricted Stock Units, Granted | shares	212,000
Number of Restricted Stock Units, Vested | shares	(285,662)
Number of Restricted Stock Units, Forfeited | shares	(33,250)
Number of Restricted Stock Units, Outstanding, March 31, 2018 | shares	573,451
Weighted Average Grant Date Fair Value per Unit, Outstanding, December 31, 2017 | $ / shares	$ 1.11
Weighted Average Grant Date Fair Value per Unit, Granted | $ / shares	0.84
Weighted Average Grant Date Fair Value per Unit, Vested | $ / shares	1.36
Weighted Average Grant Date Fair Value per Unit, Forfeited | $ / shares	1.26
Weighted Average Grant Date Fair Value per Unit, Outstanding, March 31, 2018 | $ / shares	$ 0.88

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - Significant Unobservable Inputs (Level 3) [Member] - Recurring [Member]	3 Months Ended
	Mar. 31, 2018$ / shares
Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant expiration date	May 1, 2018
Volatility rate	50.37%
Risk-free interest rate	1.63%
Closing stock price	$ 0.66
Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant expiration date	Nov. 1, 2018
Volatility rate	68.30%
Risk-free interest rate	1.93%
Closing stock price	$ 0.66

Fair Value Measurements (Assets

Fair Value Measurements (Assets And Liabilities Measured At Fair Value On Recurring Basis By Level) (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued		$ 19,574,977
Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value		19,574,977
Recurring [Member] | Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Recurring [Member] | Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued		5,746
Recurring [Member] | Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued		19,569,231
Quoted Prices In Active Markets For Identical Instruments (Level 1) [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value
Quoted Prices In Active Markets For Identical Instruments (Level 1) [Member] | Recurring [Member] | Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Quoted Prices In Active Markets For Identical Instruments (Level 1) [Member] | Recurring [Member] | Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Quoted Prices In Active Markets For Identical Instruments (Level 1) [Member] | Recurring [Member] | Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Other Observable Inputs (Level 2) [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value
Significant Other Observable Inputs (Level 2) [Member] | Recurring [Member] | Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Other Observable Inputs (Level 2) [Member] | Recurring [Member] | Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Other Observable Inputs (Level 2) [Member] | Recurring [Member] | Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value		19,574,977
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member] | Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member] | Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued		5,746
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member] | Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued		$ 19,569,231

Fair Value Measurements (Summar

Fair Value Measurements (Summary Of Changes In Fair Value Of Level 3 Financial Liabilities) (Details)	3 Months Ended
	Mar. 31, 2018USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	$ 19,574,977
Issues
Reclassifications	(16,984,616)
Settlements
Revaluation	(2,590,361)
Balance at end of period
Warrants Issued May 2012 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period
Issues
Reclassifications
Settlements
Revaluation
Balance at end of period
Warrants Issued August 2013 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	5,746
Issues
Reclassifications
Settlements
Revaluation	(5,746)
Balance at end of period
Warrants Issued September 2016 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	19,569,231
Issues
Reclassifications	(16,984,616)
Settlements
Revaluation	(2,584,615)
Balance at end of period

Product Warranty Provisions (De

Product Warranty Provisions (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Product Warranty Provisions [Abstract]
Standard product warranty coverage term	1 year
Warranty accrual, beginning of the fiscal period	$ 164,365	$ 222,845
Accrual adjustment for product warranty	(2,640)	32,679
Payments made	(16,553)	(91,159)
Warranty accrual, end of the fiscal period	$ 145,172	$ 164,365

Subsequent Events (Details)

Subsequent Events (Details) - Revolving Credit Facility [Member]	Apr. 26, 2018USD ($)	Mar. 31, 2018USD ($)	Nov. 06, 2017USD ($)
Subsequent Event [Line Items]
Line of credit facility, maximum borrowing capacity		$ 5,000,000	$ 10,000,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Line of credit facility, maximum borrowing capacity	$ 5,000,000
Minimum [Member]
Subsequent Event [Line Items]
Liquidity ratio		1.50
Streamline Period [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Line of credit interest rate	4.50%
Liquidity ratio	1.75
Streamline Period [Member] | Minimum [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Line of credit interest rate	4.50%
Liquidity ratio	1.75
Non-Streamline Period [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Interest rate added to prime rate	1.50%
Non-Streamline Period [Member] | Minimum [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Line of credit interest rate	4.50%
Cash and Cash Equivalents [Member]
Subsequent Event [Line Items]
Minimum tangible net worth requirement		$ 1,500,000
Cash and Cash Equivalents [Member] | Minimum [Member]
Subsequent Event [Line Items]
Minimum tangible net worth requirement		$ 1,500,000